Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

NCT01104311

Last updated date
Study Location
Chungnam National University Hospital
Daejeon, Chungnam, 301-721, Korea, Republic of
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Brain Ischemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- acute symptomatic ischemic stroke having relevant lesion on DWI(Diffusion weighted image) MRI 7 days after and 42 days within onset.

- relevant stenosis(more than 50%) or occlusion from MCA(middle cerebral artery)(M1) to distal of ICA(internal carotid artery ) on MR(Magnetic resonance) angiogram or CT angiogram.

- mean systolic blood pressure>=140mmHg or taking antihypertensive drug on screening.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- taking more than 3 antihypertensive drugs and mean systolic blood pressure>=150mmHg on
screening.


- history of recent thrombolysis but stenosis or occlusion remained after thrombolysis.


- evidence of orthostatic hypotension


- suspicious embolic cerebrovascular stenosis


- planned state of cerebrovascular surgery or angioplasty or stent 7 months within
screening.


- severe stroke-NIHSS>=16


- mean systolic blood pressure>=200mmHg which is not able to control on screening.


- abnormal blood test finding (abnormal LFT(liver function test), anemia, renal
insufficiency)


- pregnant or breast-feeding


- severe stroke sequela or medical problem


- suspicious secondary hypertension


- disease causing edema or significant ankle edema on screening.


- severe heart failure which correspond to NYHA (New York Heart Association )heart
failure classification class III or IV.


- inappropriate condition determined by investigator


- Patient who do not have FLAIR image on or two months prior to screening.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Brain IschemiaStrategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
NCT01104311
  1. Daejeon, Chungnam
  2. Goyang, Gyeonggi-do
  3. Iksan, Jeonbuk
  4. Busan,
  5. Daegu,
  6. Daejon,
  7. Deagu,
  8. Gwangju,
  9. Inchon,
  10. Pusan,
  11. Seoul,
  12. Seoul,
  13. Seoul,
  14. Seoul,
  15. Seoul,
  16. Seoul,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Official Title  ICMJE Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis
Brief Summary

To develop adequate blood pressure (BP) lowering strategy after subacute ischemic stroke patients with symptomatic severe intracranial atherosclerosis.

Primary hypothesis of this study is that aggressive BP control (lowering systolic BP between 110mmHg and 120mmHg) will not increase the ischemic lesion volumes in hemisphere compared to modest BP lowering (lowering systolic BP between 130mmHg and 140mmHg) in the patients with symptomatic severe intracranial atherosclerosis.

Detailed Description

The benefits of BP lowering in the prevention of primary and secondary prevention of stroke is established well, although absolute target BP level is uncertain. Current guidelines defined the normal BP as <120/80mmHg and recommend individualized target BP level.

Large well performed stroke prevention trials consistently showed that reduction of 10/5mmHg in patients with systolic BP below 140mmHg had clear benefits in the prevention of cardiovascular events. However, we have a dilemma about BP control in the patients with severe intracranial atherosclerosis.

Aggressive BP control will be more effective in the prevention of overall cardiovascular events than modest BP control, but aggressive BP control will reduce cerebral perfusion in the territory of severe intracranial disease and may increase the risk of ischemic damage.

The study will try to reveal aggressive BP control in the patients with symptomatic severe intracranial atherosclerosis is not increase ischemic lesion volume in hemisphere to compare modest BP control.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Brain Ischemia
Intervention  ICMJE
  • Procedure: Aggressive BP lowering
    adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
    Other Name: Aggressive BP control
  • Procedure: modest blood pressure lowering
    adjust the amount and number of antihypertensive drugs
    Other Name: Modest BP control
Study Arms  ICMJE
  • Experimental: Aggressive BP lowering
    Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
    Intervention: Procedure: Aggressive BP lowering
  • Active Comparator: Modest BP lowering
    Lowering of systolic blood pressure between 130mmHg and 140mmHg
    Intervention: Procedure: modest blood pressure lowering
Publications * Park JM, Kim BJ, Kwon SU, Hwang YH, Heo SH, Rha JH, Lee J, Park MS, Kim JT, Song HJ, Park JH, Yu S, Lee SJ, Park TH, Cha JK, Kwon HM, Kim EG, Lee SH, Lee JS, Lee J. Intensive blood pressure control may not be safe in subacute ischemic stroke by intracranial atherosclerosis: a result of randomized trial. J Hypertens. 2018 Sep;36(9):1936-1941. doi: 10.1097/HJH.0000000000001784.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: January 17, 2017)
132
Original Estimated Enrollment  ICMJE
 (submitted: April 14, 2010)
156
Actual Study Completion Date  ICMJE December 2015
Actual Primary Completion Date April 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • acute symptomatic ischemic stroke having relevant lesion on DWI(Diffusion weighted image) MRI 7 days after and 42 days within onset.
  • relevant stenosis(more than 50%) or occlusion from MCA(middle cerebral artery)(M1) to distal of ICA(internal carotid artery ) on MR(Magnetic resonance) angiogram or CT angiogram.
  • mean systolic blood pressure>=140mmHg or taking antihypertensive drug on screening.

Exclusion Criteria:

  • taking more than 3 antihypertensive drugs and mean systolic blood pressure>=150mmHg on screening.
  • history of recent thrombolysis but stenosis or occlusion remained after thrombolysis.
  • evidence of orthostatic hypotension
  • suspicious embolic cerebrovascular stenosis
  • planned state of cerebrovascular surgery or angioplasty or stent 7 months within screening.
  • severe stroke-NIHSS>=16
  • mean systolic blood pressure>=200mmHg which is not able to control on screening.
  • abnormal blood test finding (abnormal LFT(liver function test), anemia, renal insufficiency)
  • pregnant or breast-feeding
  • severe stroke sequela or medical problem
  • suspicious secondary hypertension
  • disease causing edema or significant ankle edema on screening.
  • severe heart failure which correspond to NYHA (New York Heart Association )heart failure classification class III or IV.
  • inappropriate condition determined by investigator
  • Patient who do not have FLAIR image on or two months prior to screening.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Korea, Republic of
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01104311
Other Study ID Numbers  ICMJE STABLE-ICAS
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Undecided
Plan Description:There is no plan to share data yet. It will be discussed with investigators who have been participating in this study.
Responsible Party Sun U. Kwon, Asan Medical Center
Study Sponsor  ICMJE Asan Medical Center
Collaborators  ICMJE Pfizer
Investigators  ICMJE Not Provided
PRS Account Asan Medical Center
Verification Date January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP